// App-Quantinova.ai

CTNI-49 : PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN ß, IN PATIENTS WITH ADVANCED SOLID TUMORS, WITH A PHASE 2 EXPANSION IN RECURRENT GLIOBLASTOMA MULTIFORME

Researchers

Presenter

  • Stefan Symeonides

Principal Investigators

  • Jeff Evans

  • Hendrik-Tobias Arkenau

  • Meredith McKean

  • Nehal Lakhani

  • Emerson Lim

  • Gerald Falchook

  • Jim Rotolo

  • Gina Capiaux

  • Rob Michel

  • Stephen Kaesshaefer

  • Alice Bexon

Medical Centers

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK

  • Sarah Cannon Research Institute at HealthONE, Denver, CO, USA

  • Sarah Cannon UK and UCL, London, London, UK

  • START Midwest, Grand Rapids, Grand Rapids, MI, USA

  • Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

  • Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA

  • Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • ST101

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Simon'S Two Stage Design

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved